Phase I/II trial of BPX-401 in patients with haematological cancer

Trial Profile

Phase I/II trial of BPX-401 in patients with haematological cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs BPX 401 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to a Bellicum Pharmaceuticals media release, the company expects to initiate this trial in the fourth quarter of 2017.
    • 09 May 2016 According to a Bellicum Pharmaceuticals media release, the company plans to initiate the clinical development of BPX-401 in the second half of 2016.
    • 17 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top